Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab

Archives of Dermatology

Volumn 147, Issue 10, 2011, Pages 1203-1205

  Guenova, Emmanuella ^a   Teske, Anna ^a   Fehrenbacher, Birgit ^a   Hoerber, Sebastian ^a   Adamczyk, Annette ^a   Schaller, Martin ^a   Hoetzenecker, Wolfram ^a   Biedermann, Tilo ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12P35; INTERLEUKIN 17; INTERLEUKIN 23; PREDNISOLONE; TACROLIMUS; USTEKINUMAB;

ARTICLE; CLINICAL EXAMINATION; CLINICAL FEATURE; DISEASE COURSE; DRUG TARGETING; DRUG TREATMENT FAILURE; FOLLOW UP; HISTOLOGY; HUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PYODERMA GANGRENOSUM; SKIN BIOPSY; SKIN ULCER; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-23; MOLECULAR TARGETED THERAPY; PYODERMA GANGRENOSUM; TACROLIMUS; TREATMENT OUTCOME;

EID: 80054754826     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2011.168     Document Type: Article

References (15)

1. Powell FC, Perry HO. Pyoderma gangrenosum in childhood. Arch Dermatol. 1984;120(6):757-761. (Pubitemid 14084652)
2. Bennett ML, Jackson JM, Jorizzo JL, Fleischer AB Jr, White WL, Callen JP. Pyoderma gangrenosum: a comparison of typical and atypical forms with an emphasis on time to remission: case review of 86 patients from 2 institutions. Medicine (Baltimore). 2000;79(1):37-46. (Pubitemid 30077735)
3. Miller J, Yentzer BA, Clark A, Jorizzo JL, Feldman SR. Pyoderma gangrenosum: a review and update on new therapies. J Am Acad Dermatol. 2010;62(4):646-654.
4. Callen JP. Pyoderma gangrenosum. Lancet. 1998;351(9102):581-585. (Pubitemid 28077573)
5. von den Driesch P. Pyoderma gangrenosum: a report of 44 cases with follow-up. Br J Dermatol. 1997;137(6):1000-1005.
6. Crowson AN, Mihm MC Jr, Magro C. Pyoderma gangrenosum: a review. J Cutan Pathol. 2003;30(2):97-107. (Pubitemid 36384853)
7. Abraham C, Cho JH. IL-23 and autoimmunity: new insights into the pathogenesis of inflammatory bowel disease. Annu Rev Med. 2009;60:97-110.
8. Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005;201(2):233-240. (Pubitemid 40189432)
9. Reichrath J, Bens G, Bonowitz A, Tilgen W. Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol. 2005;53(2):273-283. (Pubitemid 40979585)
10. Conrad C, Trüeb RM. Pyoderma gangrenosum. J Dtsch Dermatol Ges. 2005;3(5):334-342. (Pubitemid 40754639)
11. Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13(5):715-725.
12. Kastelein RA, Hunter CA, Cua DJ. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol. 2007;25:221-242. (Pubitemid 46697908)
13. Neurath MF, Fuss I, Kelsall BL, Stüber E, Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med. 1995;182(5):1281-1290.
14. Krueger GG, Langley RG, Leonardi C, et al. CNTO 1275 Psoriasis Study Group. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007;356(6):580-592. (Pubitemid 46220818)
15. Toichi E, Torres G, McCormick TS, et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol. 2006;177(7):4917-4926. (Pubitemid 44469828)